Author(s):
Kunisetti Nagendra Babu, Devi Thamizhanban, Bibhash Chandra Mohanta, K. Lakshmi
Email(s):
devit@care.edu.in
DOI:
10.52711/0974-360X.2024.00753 
Address:
Kunisetti Nagendra Babu1, Devi Thamizhanban1*, Bibhash Chandra Mohanta2, K. Lakshmi1
1Chettinad School of Pharmaceutical Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam - 603103, Tamilnadu, India.
2Department of Pharmacy, Central University of South Bihar, Gaya-824236, Bihar, India.
*Corresponding Author
Published In:
Volume - 17,
Issue - 10,
Year - 2024
ABSTRACT:
This study investigates the use of lipid polysaccharide hybrid nanoparticles (LPHNPs) as a drug delivery vehicle for Vildagliptin. The researchers used a nanoprecipitation strategy with PLGA and soybean phosphatidylcholine to create stacked LPHNPs. The study discovered that the nanosized and round LPHNPs had a similar size distribution and significantly improved drug absorption and dissolution in the crossbreed network. The content of polymer led to a rise in the size of the nanoparticles, while the content of lipid and polymer enhanced the efficacy of drug entrapment. The in vitro drug release ranged from 72-94%, and the delivery components followed the Korsmeyer-Peppas model and Fickian diffusion. The study suggests that PLGA and soybean phosphatidylcholine-based framework LPHNPs could be promising for improving Vildagliptin dissolution and increasing its profile accessibility.
Cite this article:
Kunisetti Nagendra Babu, Devi Thamizhanban, Bibhash Chandra Mohanta, K. Lakshmi. PLGA (Poly lactic-co-glycolic acid) and Soybean Phosphatidylcholine loaded Vildagliptin Lipid Polysaccharide Hybrid Nanoparticles: Development and Assessment for Oral Delivery Operations. Research Journal of Pharmacy and Technology. 2024; 17(10):4895-0. doi: 10.52711/0974-360X.2024.00753
Cite(Electronic):
Kunisetti Nagendra Babu, Devi Thamizhanban, Bibhash Chandra Mohanta, K. Lakshmi. PLGA (Poly lactic-co-glycolic acid) and Soybean Phosphatidylcholine loaded Vildagliptin Lipid Polysaccharide Hybrid Nanoparticles: Development and Assessment for Oral Delivery Operations. Research Journal of Pharmacy and Technology. 2024; 17(10):4895-0. doi: 10.52711/0974-360X.2024.00753 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2024-17-10-38
REFERENCES:
1. Bonagiri Sreedevi, Vijaya Kuchana, S. Shobharani. Estimation of Anti-Diabetic property of Holarrhena pubescens by In Vitro method using L6 rat Skeletal Muscle Cell Lines. Research J. Pharm. and Tech. 2020; 13(12): 6238-6242. doi: 10.5958/0974-360X.2020.01087.2
2. who.int [Internet]. World health organization [updated 5 April 2023].
3. Yan-Ling He. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet. 2012; 51(3): 147-62. doi: 10.2165/11598080-000000000-00000.
4. Saloni Manglik, Jaya Singh. A Review on Nanoparticles: Preparation and Characterization of Nanoparticles. Research Journal of Topical and Cosmetic Sciences. 2021; 12(2): 79-5. doi: 10.52711/2321-5844.2021.00011.
5. Hemanth A. R., G. B. Kiran Kumar, Prakash Goudanavar, Dhruva Sagar S. Formulation and Evaluation of Hydrogels containing Liposomes Entrapped with Antifungal Agent. . Research J. Pharm. and Tech. 2021; 14(9): 4947-0. doi: 10.52711/0974-360X.2021.00860
6. Ch.Prabhakar, K. Bala Krishna. A Review on Polymeric Nanoparticles. Research J. Pharm. and Tech. 2011; 4(4): 496-498.
7. Vivek Davea, Kajal Taka, Amit Sohgaura, Ashish Gupta, Veera Sadhu, Kakarla Raghava Reddy. Lipid-polymer hybrid nanoparticles: synthesis strategies and biomedical applications. J. Microbiol. Methods. 2019; 160: 130–142. doi: 10.1016/j.mimet.2019.03.017.
8. Rajesh B. Nawale, Uday A. Deokate, Sadhana R. Shahi, Pradeep M. Lokhande. Formulation and Characterization of Efavirenz Nanosuspension by QbD approach. Research J. Pharm. and Tech 2017; 10(9): 2960-2972. doi: 10.5958/0974-360X.2017.00525.X
9. Nitin Rajendra Shirsath, Ajaygiri Kamalgiri Goswami. Design and development of sustained release vildagliptin-loaded silica nanoparticles for enhancing oral bioavailability. BioNanoScience. 2021; 11: 324–335.doi: 10.1007/s12668-021-00865-y.
10. Irfan M. Saiyyad, D. S. Bhambere, Sanjay Kshirsagar. Formulation and Optimization of Silymarin Loaded PLGA Nanoparticle for liver targeting. Asian J. Pharm. Tech. 2017; 7(4): 209-220 . doi: 10.5958/2231-5713.2017.00032.0
11. Nayab Tahira, Asadullah Madnia et.al., Development and optimization of methotrexate-loaded lipid-polymer hybrid nanoparticles for controlled drug delivery applications. Int J Pharm Pharm Sci. 2017; 533: 156–168.doi:doi: 10.1016/j.ijpharm.2017.09.061.
12. Ameeduzzafar, Ibrahim El-Bagory, Nabil K. Alruwaili et.al., Development of novel dapagliflozin loaded solid self-nanoemulsifying oral delivery system: Physiochemical characterization and in vivo antidiabetic activity. J Drug Deliv Sci Technol. 2019; 54: 101279.doi: 10.1016/j.jddst.2019.101279
13. Priyanka Shrestha, Shiva Kumar Bhandari, SM Ashraful Islam, Md Selim Reza, and Santosh Adhikari. Design and development of immediate and sustained release tablets of vildagliptin. BioNanoScience. 2021;11:324–335.
14. Sudarshan B. Kakad, Punit R. Rachh. Design, development, and characterization of immediate release matrix tablet of vildagliptin. Int. J. Pharm. Qual. Assur, 2021; 12(4): 303-308. doi: 10.25258/ijpqa.12.4.14
15. Jitendra B. Naik, Mrunal R. Waghulde. Development of vildagliptin loaded Eudragit® microspheres by screening design: in vitro evaluation. J Pharm Investig. 2018; 48: 627–637. doi: 10.1007/s40005-017-0355-3.